GILD News and Press, Gilead Sciences Inc. From 05/27/24

2024-05-27 01:45:30 ET Summary Gilead is sitting at one of the lowest valuations in the Big Pharma sector, with a high and sustainable 4.6% dividend yield available for new buyers. The stock has an enviable track record of rising strongly in price when turmoil hits Wall Street and...

2024-05-26 05:30:00 ET Summary Parnassus Investments is a fundamental, bottoms-up investment firm offering responsible investment funds to the public. Parnassus Investments integrates comprehensive ESG evaluations with fundamental financial analysis to select investments. The Fund...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-24 15:00:53 ET More on the markets S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight SPY ETF: Momentum Is In The Cards Stocks have more room to run - Invesco's Kristina Hooper Big bear Mike Wilson changes tune a...

2024-05-24 06:05:00 ET Summary Dodge & Cox Stock Fund seeks long-term growth of principal and income, with a secondary focus on achieving a reasonable current income. U.S. equity markets rose to all-time highs during the first quarter of 2024, extending the robust perform...

2024-05-23 07:00:00 ET Summary Gilead Sciences has a 4.5% yield. The company has struggled with declining profits and sales in recent years. The company's growth potential lies in its HIV and oncology treatments, but it faces competition and disappointing trial results. Gilead...

– Key Findings from PBC, HDV, HCV, HBV and MASH/Fibrosis Studies Affirm Commitment to Drive Life-changing Science in Liver Disease – Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the ...

NORTHAMPTON, MA / ACCESSWIRE / May 21, 2024 / Driven by our purpose to make the world a healthier place for all people, we've worked to improve health equity and advance equitable access to care. Last week, we brought together leaders, advocates and changemakers to share insights at our inaugura...

2024-05-20 12:37:35 ET More on Gilead Sciences Biopharma M&A surges year over year in Q1 Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript) ...

2024-05-19 14:00:55 ET More on pharma companies Novo Nordisk, J&J lead R&D rankings in big pharma: report Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Johnson & Johnson: Buy This Bargain Before It's Gone ...